BioNTech | 6-K: Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BioNTech | 6-K: Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BioNTech | 6-K:研究性Acasunlimab与Pembrolizumab联合使用在接受过治疗的转移性非小细胞肺癌患者中进行的2期试验中表现出显著的临床活性